Salmosan Vet, 500 mg/g Powder for Suspension for Fish Treatment

Country: United Kingdom

Language: English

Source: VMD (Veterinary Medicines Directorate)

Active ingredient:

Azamethiphos

Available from:

Benchmark Animal Health Limited

ATC code:

QP53AF17

INN (International Name):

Azamethiphos

Pharmaceutical form:

Powder for suspension for fish treatment

Prescription type:

POM-V - Prescription Only Medicine – Veterinarian

Therapeutic group:

Atlantic salmon

Therapeutic area:

Ectoparasiticide

Authorization status:

Authorized

Authorization date:

2014-12-10

Summary of Product characteristics

Revised: December 2022
AN: 02732/2022
Page 1 of 9
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Salmosan Vet, 500 mg/g Powder for Suspension for Fish Treatment.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each gram contains:
Active substance:
Azamethiphos 500 mg
Excipients:
For the full list of excipients see Section 6.1
3.
PHARMACEUTICAL FORM
Powder for suspension for fish treatment.
Light beige to beige powder.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Farmed Atlantic salmon (_Salmo salar_)
4.2
INDICATIONS FOR USE (SPECIFYING THE TARGET SPECIES)
For treatment of pre-adult to adult sea-lice (_Lepeophtheirus
salmonis_ or
_Caligus_ species) on farmed Atlantic salmon.
4.3
CONTRAINDICATIONS
Do not use the product in cases of known hypersensitivity to the
active
substance or any of the excipients.
4.4
SPECIAL WARNINGS (FOR EACH TARGET SPECIES)
The product does not treat juvenile attached sea lice which may be
present
with the pre-adult and adult stages. These juvenile stages will
develop into
pre-adults and adults in 10 to 20 days when the population count
should
show whether a second treatment is necessary. All fish on the site
should
be simultaneously treated.
Revised: December 2022
AN: 02732/2022
Page 2 of 9
Resistance is known to occur where incomplete treatments are carried
out.
To help prevent resistance occurring ensure the correct dose and
duration
of treatment is accomplished. Only fully enclosed treatments should be
used. Repeated use of the same class of chemotherapeutic agent may
result in the development of resistance. In order to reduce the risk
of
resistance to the product developing, the product should be used as
part of
a rotational strategy in the medicinal treatment of sea lice.
Where there are concerns of decreasing sensitivity of lice to
Azamethiphos
based products the maximum treatment time (60 minutes) should be used
to
achieve
optimum
efficacy
and
limit
the
opportunity
for
resistance
development (see also Section 4.5).
Do not use the product prophylactically.